新华制药(000756.SZ)：获得缬沙坦胶囊药品注册证书

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received the drug registration certificate for Valsartan capsules from the National Medical Products Administration, indicating a significant step in its product portfolio aimed at treating mild to moderate primary hypertension [1] Group 1 - The approval of Valsartan capsules is a regulatory milestone for Xinhua Pharmaceutical, enhancing its position in the hypertension treatment market [1] - Valsartan is specifically indicated for the treatment of mild to moderate primary hypertension, which addresses a substantial patient population [1]